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Abstract 
 
Purpose of Review. Atherosclerosis is an inflammatory disorder of the arterial wall, in which several players 
contribute to the onset and progression of the disease. Beside the well established role of lipids, specifically 
cholesterol, and immune cell activation, new insights on the molecular mechanisms underlying the 
atherogenic process have emerged.  
Recent Findings. Meta-inflammation, a condition of low-grade immune response caused by metabolic 
dysregulation, alteration of the non-classical immunological memory of innate immune cells (referred to as 
“trained immunity”), cholesterol homeostasis in dendritic cells and immunometabolism, i.e. the interplay 
between immunological and metabolic processes, have all emerged as new actors during atherogenesis. 
These observations reinforced the interest in directly targeting inflammation to reduce cardiovascular 
disease. 
Summary. The novel acquisitions in pathophysiology of atherosclerosis reinforce the tight link between 
lipids, inflammation and immune response, and support the benefit of targeting LDL-C as well as 
inflammation to decrease the CVD burden. How this will translate into the clinic will depend on the balance 
between costs (monoclonal antibodies either to PCSK9 or to IL-1ß), side effects (increased incidence of 
death due to infections for anti-IL-1ß antibody) and the benefits for patients at high risk. 
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Inflammation, immune response and atherosclerosis: which role for lipids and lipoproteins? 
Atherosclerosis is a pathological condition characterized by a chronic, non-resolving low-grade 
inflammation within the arterial wall resulting from the accumulation of apoB-containing lipoproteins in 
sites where disturbed laminar flow is present [1]. This event triggers the recruitment of monocyte-
macrophages, the most abundant immune cells present in atherosclerotic lesions, and cells of adaptive 
immune response such as T lymphocytes [1].  
Aim of this review is to discuss the emerging concepts in the field of immunity and atherosclerosis with a 
main focus on the interplay among lipids, cellular metabolic functions and immune cells activation. 
Cholesterol is an essential component of cellular membranes; lipid rafts are microdomains of the plasma 
membrane that are enriched in cholesterol and sphingolipids and serve as a platform in which proteins 
involved in signal transduction pathways transiently converge to trigger a cellular response [2]. In the 
context of atherosclerosis, lipid rafts are involved in the regulation of several processes including immune 
cell activation, inflammation, and proliferation of smooth muscle cells [2]. Alterations in the lipid 
composition of lipid rafts, and in particular in their cholesterol content, following the interaction with 
plasma lipoproteins, may lead to changes of lipid raft-dependent signaling; such alterations include either 
cholesterol enrichment, triggered by the cholesterol transported in LDL, or cholesterol depletion, induced 
by HDL [2]. LDL and oxidized LDL (specifically oxysterols) increase the formation of lipid rafts, which in turn 
support the translocation of proteins including NADPH oxidase, transient receptor potential channel-1 
(TRPC-1) or endothelial nitric oxide synthase, all leading to increased oxidative stress, calcium-mediated 
apoptosis, secretion of pro-inflammatory cytokines and inhibition of nitric oxide secretion [2]; conversely, 
HDL-mediated-raft reduction contributes to the maintenance of endothelial integrity [2-5]. Lipid rafts also 
play a role in immune cells signaling by assisting the formation of immunological synapses, specialized 
membrane regions in which receptors essential for immune cell activity, including toll like receptors (TLRs), 
T cell receptor (TCR) and B cell receptor (BCR) as well as major histocompatibility complex (MHC) molecules 
are located [6]. Studies on lymphocytes showed that aggregation of membrane rafts facilitates cell signaling 
after TCR ligation [7] and that accumulation of cholesterol in T cells from patients with systemic lupus 
erythematosus lowered the threshold for activation and TCR signaling leading to aberrant immune 
response [8]. Lipid rafts are also involved in antigen presentation by harboring MHCII and thus playing a key 
role in APC-mediated T cell activation and proliferation [9]. Disruption of these domains alters MHCII 
localization in raft microdomains and dramatically inhibits antigen presentation [10]; similar findings were 
reported in macrophages where selective deficiency of ATB-binding cassette transporter A1 (ABCA1) leads 
to increased MyD88-dependent TLRs recruitment to lipid rafts [11] thus changing macrophage toward an 
hyper-responsive phenotype to LPS challenge.  
The imbalance between the rate of cholesterol uptake and the rate of cholesterol removal through efflux 
mechanisms in immune cells, however, does not only affect lipid rafts biology but also favors the 
accumulation of cholesteryl esters (CE) [12]. This may occur already in circulating mononuclear cells which 
become enriched in cholesterol when plasma levels of LDL are high and levels of HDL are low. Cholesterol-
enriched monocytes are more likely to adhere to a damaged endothelium and migrate into the intima [13-
15], where they differentiate into macrophages. Indeed, lipid accumulation in monocytes, which has been 
observed in the postprandial phase and associated with increased activation in individuals with metabolic 
syndrome, may promote atherogenesis by facilitating their adhesion and transendothelial migration [16]. 
Here, macrophages may further take up modified lipoproteins through scavenger receptors and become 
foam cells. Following the uptake of lipoproteins, CE present in the core are hydrolyzed to free cholesterol 
(FC); in the presence of excess FC, which can induce membrane damage and cytotoxicity, compensatory 
mechanisms are activated to reduce cholesterol synthesis and uptake and increase cholesterol efflux [17]. 
When these mechanisms fail, FC is re-esterified for storage in lipid droplets, which are metabolically active 
intracellular organelles composed by a hydrophobic core of neutral lipids surrounded by a phospholipid 
monolayer coated with specific proteins and are believed to contribute to the development of 
atherosclerosis [17, 18].   
Although this mechanism is initially protective, the continuous accumulation of lipid droplets may shift 
macrophages to a long term pro-inflammatory phenotype. This profile appears to be the consequence of 
the acquisition by innate immune cells of an memory which differs from what observed in cells of the 
adaptive arm of the immune system [19, 20]. This phenomenon is referred to as “trained immunity” or 
innate immune memory (Figure 1). Trained immunity is based on epigenetic reprogramming, i.e. sustained 
changes in transcription programs following changes in chromatin organization, histone modifications and 
persistence of microRNAs induced by the first exposure to the dangerous stimulus [19]. This leads to an 
increased pro-inflammatory response and may help to explain the basis of the well established relationship 
between infection and atherosclerosis [21]. In the context of atherosclerosis, trained immunity may be 
induced also by non-microbial stimuli, such as oxidized LDL (OxLDL) or lipoprotein(a) [Lp(a)] [22, 23]. 
Experimental data suggest that a brief stimulation of monocytes with low concentrations of OxLDL (but not 
LDL) results in epigenetic histone modifications leading to increased production of pro-inflammatory 
cytokines and foam cell formation following re-stimulation [22]. The activation of trained immunity appears 
to be also related to Lp(a). Indeed subjects with elevated Lp(a) levels not only exhibit increased arterial 
inflammation, but also present monocytes which remain in a long-lasting primed state characterized by an 
enhanced capacity to adhere and transmigrate the endothelium and increased production of pro-
inflammatory cytokine following TLR stimulation [23]. In addition, Lp(a) primes monocytes toward a 
responsive state, resulting in an increased production of pro-inflammatory cytokines upon restimulation 
[23]. Due to the short half-life of monocyte-macrophages, the concept of trained immunity implies that 
such epigenetic changes must be maintained by similar changes in hematopoietic precursor cells in the 
bone marrow [24]. Altogether these observations suggest that, although trained immunity may represent a 
valuable way to protect the host against recurrent infections, it might contribute and even accelerate the 
development of atherosclerosis. Cholesterol crystals accumulation in the extracellular space may damage 
and activate intimal surface, thus resulting in the production of pro-inflammatory cytokines that promote 
the growth as well as atherosclerotic plaque destabilization [25-27]. 
 
Emerging immuno-players in atherosclerosis 
At the molecular level, the enrichment of lipid rafts with cholesterol leads to the formation of cholesterol 
crystalline membrane domains which precedes the release of cholesterol crystal in the extracellular space 
[28]. Cholesterol crystals initiate inflammation via NLRP3 inflammasome activation, leading to the secretion 
of IL-1ß [29]. The inflammasome is a cytoplasmic complex containing multiple proteins, which is formed in 
response to damage/danger-associated molecular patterns (DAMPs) or pathogen-associated molecular 
patterns (PAMPs) expressed by macrophages, and serves as a molecular platform for the activation of the 
cysteine protease caspase-1 [29]. Several types of inflammasome complexes have been reported but only 
the activation of NLRP3 inflammasome and consequent inflammatory responses contributes to the 
progression of atherosclerosis [30]. Current data indicate that OxLDL triggers an inflammatory “priming” 
[31], which is followed by cholesterol crystal-mediated activation of the inflammasome [32, 33]. Causality 
of this mechanism in atherogenesis has been demonstrated in LDLR KO mice in which the deficiency of 
NRLP3 in bone marrow cells protects from the disease [34]. Release of IL-1β and IL-18 pro-inflammatory 
cytokines following NRLP3 activation promotes atherosclerosis and the use of animal models have clearly 
demonstrated, with few exceptions [32, 35], that their deficiency as well as deficiency of caspase-1 reduces 
the size of atherosclerotic lesions [36-39]. 
More recently, metabolically-driven inflammation, known as meta-inflammation, was postulated to be 
critical in explaining the deep connection among obesity, diabetes and atherosclerosis (Figure 2). [40]. 
Meta-inflammation is a chronic low-grade inflammation connecting alterations in systemic metabolism 
with the impairment in immune cells cellular metabolism and function [41]. The close relationship between 
metabolism and immuno-inflammation is further supported by the observation that NLRP3-deficient mice 
on a high-fat diet become insulin hypersensitive [42], thus suggesting that inflammasome is somehow 
linked to insulin action; in humans increased levels of LDL-C induce pro-IL-1β production through TLRs [43], 
and saturated fatty acids, such as palmitate and stearate, activate NLRP3 in primed macrophages in a ROS- 
and AMPK-dependent manner [44]. In mice, dyslipidemia induced by deficiency of key genes involved in 
cholesterol homeostasis, such as apolipoprotein E or ATP-binding cassette A1 or G1, promotes 
myelopoiesis and extramedullary hematopoiesis, resulting in increased levels of circulating monocytes and 
inflammatory response, as the consequence of cholesterol enrichment in lipid rafts of immune cells [45-
47]. These observations have driven the research toward the investigation of the impact of intracellular 
lipid alteration in immune cell function, a field known as immunometabolism [41] which shares molecular 
mechanisms of pathogenicity with cardiometabolic diseases, autoimmunity and cancer. Lipid homeostasis 
is finely regulated by transcription factors namely liver X receptors (LXR) and sterol regulatory-element 
binding proteins (SREBP) which sense cholesterol and lipid concentration thus promoting lipid removal or 
biosynthetic pathways respectively [48]. This dichotomy has been widely investigated in macrophages 
where, following inflammation, de-novo lipogenesis is required to support inflammasome activation [49], 
and later (12-24 hours following TLR4 activation) plays a key role in the resolution phase by producing anti-
inflammatory fatty acids [50]. Also the activation of LXR is known to be anti-inflammatory as it represses 
TLRs 2,4 and 9-dependent NF-кB activation via modulation of ABCA1-mediated cholesterol efflux, lipid raft 
enrichment and TLRs localization in the membranes [51]. The notion that cholesterol is an important 
component of cell membrane and is essential for cell growth and proliferation [52] can likewise be applied 
to the adaptive immune responses where lymphocytes undergo rapid expansion in response to antigenic 
challenge. Activation of LXR during T cell priming inhibits mitogen-driven expansion, with deficiency of LXRβ 
conferring a proliferative advantage [53]; on the contrary, SREBP signaling is critical for membrane 
synthesis during blastogenesis and T cells expansion [54]. Once proliferated, immune cells migrate from the 
lymph nodes toward  the inflamed tissues where they have to adapt to a different microenvironment with 
a specific extracellular matrix, growth factors, oxygen, nutrients, and metabolites [55]. As an example, in 
metabolically demanding environment such as tumors but also in atherosclerotic plaques, infiltrating 
immune cells change their immunometabolic settings and function [55]. Indeed, tissue/local enrichment of 
certain metabolites affects immune cell function as in the case of i) lactic acid, which is produced during 
hypoxia at the site of inflammation and contribute to disrupting T cell motility and reducing cytolytic 
function of CD8 T cells [56], or of ii) saturated fatty acid which are released by adipose tissue and 
differently  affect differentiation and trafficking patterns of CD4 T cells [57].  
Dendritic (DCs) cells play a key role in antigen processing and presentation and are therefore fundamental 
in connecting innate and adaptive immune response [58]. DCs migrate to lymphoid tissues to support the 
priming of selective antigen-reactive T cell clones [59] and actively participate in all stages of atherogenesis 
from fatty streaks to mature lesions formation [60]. DCs undergo an extensive differentiation program 
where balance of intracellular metabolism plays a crucial role. Lipid overload in DCs which are deficient in 
ABCA1/ABCG1 exacerbates autoimmune disease [12] and inflammasome activation [61], thus suggesting 
that cholesterol efflux pathways in these cells play a key role in the maintenance of immune tolerance. 
These findings suggest that the removal of cholesterol excess could be considered a therapeutic target to 
limit the immuno-inflammatory response in the context of atherosclerosis and also of autoimmune 
diseases where HDL are less efficient in promoting cholesterol efflux [62, 63]. In vitro, stimulation of HDL-
dependent reverse cholesterol transport disrupt lipid rafts, attenuate antigen presentation in DCs [64] and 
ameliorate autoimmune disease in mice [12]. Whether targeting cholesterol mobilization in immune cells 
will transfer in beneficial effect in the context of atherosclerosis, beyond the null effect of increasing 
plasma HDL-C levels, remains to be addressed.  
 
Targeting inflammation to reduce cardiovascular burden: a lesson from the clinical trials 
The key role of inflammation in atherosclerosis supports the hypothesis that targeting the immune-
inflammatory response will have a beneficial impact on disease outcome. 
Is there scientific evidence supporting this hypothesis?  
Statins, by promoting LDL-R expression and LDL-C reduction, demonstrated a significant and robust benefit 
in terms of cardiovascular risk reduction [65, 66] and effect also ascribed to their ability to decrease 
circulating inflammatory markers such as CRP and to improve endothelial function and plaque burden, 
effects which were associated to their potential pleiotropic activities [67]. Despite a large interindividual 
variability in LDL-C reductions following statin therapy [68], an extensive meta-analysis of clinical trials with 
statins showed the tight dependence of CRP reduction on LDL-C reduction [69]. Studies with other lipid 
lowering drugs such as ezetimibe showed that the beneficial effect of LDL-C-lowering therapies on systemic 
inflammatory status, as monitored by changes in CRP plasma levels, could be achieved, independently of 
the mechanism of action, mainly in patients already presenting with baseline inflamed conditions [70]. 
More importantly, Mendelian randomization studies have demonstrated that CRP is not a causal factor for 
atherosclerosis but a rather aspecific marker of systemic inflammation [71-75]. In many clinical trials with 
PCSK9 inhibitors, including the large outcome trial with evolocumab (FOURIER) [76], baseline levels of CRP 
were below 2 mg/L [70]. In the FOURIER study, neither the treated arm nor the placebo arm experienced a 
reduction of CRP compared to baseline in spite of a substantial LDL-C reduction in the treated arm [76]. A 
similar trend was observed in many other trials where, in patients with CRP below 2 mg/L at baseline, LDL-
C-lowering therapies, from statins to ezetimibe to anti-PCSK9 antibodies, did not affect CRP levels, perhaps 
because these patients did not present a relevant systemic inflammation [70]. Of note, even in patients 
with a CRP is below 2 mg/L and not altered by the therapy, such as in the GLAGOV study, LDL-C reduction 
with anti-PCSK9 antibodies results in atherosclerotic plaque regression as determined by IVUS [77]. These 
observations strengthen the direct link between cholesterol and atherosclerosis and indicate that 
decreasing LDL levels is one of the key goals for improving cardiovascular outcome beyond tuning 
inflammation.  
Do we have evidence for anti-inflammatory treatments on cardiovascular outcome? While most of the 
studies with anti-inflammatory agents failed to show a relevant benefit in terms of cardiovascular risk 
reduction, the results from the CANTOS trial with a monoclonal antibody (canakinumab) targeting IL-1ß 
demonstrated a benefit on cardiovascular outcome [78]. Patients with a previous myocardial infarction and 
an elevated level of high-sensitivity C-reactive protein received one of three doses of canakinumab (50, 150 
and 300 mg) or placebo [78]. The treatment with the antibody (150 mg) resulted in a significant lower 
incidence of the primary end point (a composite of nonfatal myocardial infarction, nonfatal stroke, and 
cardiovascular death) vs placebo [78]. The reduction was mainly driven by a reduction in the incidence of 
myocardial infarction [78]. The benefit occurred in the absence of a difference in the LDL-C among groups. 
How can we reconcile these observations? Targeting IL-1ß is downstream of the inflammasome activation 
driven by cholesterol. Therefore, a cholesterol driven pathway is addressed with this therapy therefore not 
surprisingly the results are similar to what can be expected by a cholesterol reduction in these patients. 
Indeed, would have been very informative if the authors were o implement an arm with patients treated 
with a PCSK9 inhibitor. 
Further, is targeting IL-1ß as safe as targeting the LDL-R pathway in terms of side effects? Data from a 
pooled analysis of the three doses of canakinumab used in the CANTOS trial showed a significantly increase 
in the deaths from infection compared to those who received placebo [78]. The investigators noted an 
intriguingly lower risk of cancer mortality with canakinumab than with placebo [79], and so there was a 
neutral effect on overall mortality.  
These data indicate the need for potential novel drugs targeting inflammation in the context of 
atherosclerosis to further scrutinize the potential negative effects of modulating the immune response 
which as could result in a reduced ability of the immune system to react toward the infections. Moreover, 
given that available lipid lowering therapies limit vascular inflammation by reducing LDL levels without 
relevant effects on infections, clinical approaches should target the axis lipids-lipoproteins-inflammation to 
achieve a cardiovascular benefit. 
 
Current scenario  
Atherosclerosis is up-to-date recognized as a chronic inflammatory disease where lipids, inflammation and 
immune response in concert contribute to the pathophysiology of the disease [80, 81]. IL-1ß has been 
proposed as a key player linking inflammation to atherogenesis and several other candidates which limit 
the inflammatory burden of atherosclerosis, as IL-18, CD40/CD40L and CCR2 have been identified [82-88]. 
In humans, pharmacological targeting of IL-1ß was proven to reduce coronary artery disease [78]; however, 
other types of interventions, including the inhibition of lipoprotein-associated phospholipase A2 (LP-PLA2) 
with darapladib [89], or TNF-mediated response with the anti-TNF strategies, have failed in clinical trials to 
reduce cardiovascular events [90]. These results suggest that inhibiting inflammation “tout court” does not 
always translate in a beneficial effect on CVD but rather appropriate pathways should be targeted from a 
clinical perspective. Moreover, a deep understanding of immune-inflammatory mechanisms playing a 
pathological role versus those which are bystanders of the inflammatory response is needed. Of note, the 
maintenance of a proper functional immune response is critical to minimize the risk of infection; a better 
identification of patients that will benefit most from Il-1beta inhibition should be performed also with the 
aim of minimizing the increased risk of death associated to sepsis in the CANTOS study.  
 
Future directions 
The increased understanding of molecular basis of cardiovascular diseases is moving clinical practice 
toward the “precision medicine” shaped on patient with a unique signature of disease. Indeed, although 
statin decrease cholesterol levels and cardiovascular events, some patients do not fully benefit of the 
treatment, due to the persistence of a residual risk. Identification of selected biomarkers will help clinicians 
choosing a personalized therapy based on patient’s disease traits; this is the case of hs-CRP that, above 2 
mg/L, provides a solid rationale for the use of an anti-inflammatory strategies on top of lipid-lowering 
drugs. On the other hand, anti-IL-1ß therapy do not fit all patients and indeed showed to reduce CHD only 
in those patients which demonstrated a significant reduction of CRP after three months on treatment [91], 
suggesting a biomarker to track for personalizing the therapy. 
 
Concluding remarks 
The CANTOS trial provides a reliable rationale for targeting  inflammation beyond controlling plasma lipids. 
As cholesterol is known to promote plaque inflammation via inflammasome activation, it is conceivable 
that, by targeting Il-1 beta on the top of lowering plasma lipids, the net effect of cholesterol in promoting 
atherosclerosis and CVD might be further dampened. 
Whether similar conclusions will result from the CIRT trial, aimed at evaluating the cardiovascular benefit of 
low-dose methotrexate, a drug with systemic anti-inflammatory effects, in patients with prior myocardial 
infarction and type 2 diabetes or metabolic syndrome remains to be seen [92] but will contribute to 
understand whether we should “tailor” the anti-inflammatory strategy in the context of atherosclerosis or 
whether what counts is to limit inflammation.  .  
Legends to the Figures 
 
Figure 1. Innate immune memory enhances immune cell activation. Innate immune memory, also referred 
to as trained immunity, originates from epigenetic reprogramming, i.e. sustained changes in transcription 
programs following changes in chromatin organization, histone modifications and persistence of 
microRNAs, which are induced by the first exposure to the dangerous stimulus. In the context of 
hypercholesterolemia, continuous accumulation of intracellular lipid droplets may shift immune cells to a 
long term pro-inflammatory phenotype which results in an exceeding immune response after immune 
challenge.  
 
Figure 2. Meta-inflammation balances functional and metabolic plasticity of immune cells. Obesity, 
diabetes and atherosclerosis share a typical activation of the immuno-inflammatory response known as 
meta-inflammation, a chronic low-grade inflammation connecting alterations in systemic metabolism with 
the impairment in immune cells cellular metabolism and function, i.e. immunometabolism. Meta-
inflammation is associated with a shift of immune cell toward an activated phenotype associated with 
activation of the inflammasome, aberrant proliferation of lymphocytes and enhanced stimulation of 
macrophages and dendritic cells.  
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